GlassScriptPhysician profile
Alexa Toohey
NPI 1831673730
$4,264.66
in general payments reported to CMS, 2019-2025
26 companies · $1,312 in 2025
The $1,312 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $305 · 2023: $1,029 · 2024: $1,619 · 2025: $1,312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,634 · Education: $326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,633.85 |
| Education | $325.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $620.83 | 2022-2025 | |
| Abbvie INC. | $595.22 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $368.51 | 2023-2025 | Ilumya |
| Janssen Biotech, INC. | $283.02 | 2022-2025 | Tremfya |
| Lilly USA, LLC | $281.66 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $277.85 | 2022-2025 | Sotyktu |
| Pfizer INC. | $213.55 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $164.45 | 2023-2025 | |
| Amgen INC. | $156.12 | 2023-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $154.37 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.73 | 2022-2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $141.19 | 2023-2025 | Jublia, Cabtreo, Arazlo |
| Dermavant Sciences, INC. | $118.86 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $106.30 | 2023-2025 | Aklief, Oracea, Nemluvio |
| Incyte Corporation | $105.51 | 2022-2024 | Opzelura |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Almirall LLC | $93.19 | 2022-2025 | Seysara, Klisyri |
| Verrica Pharmaceuticals INC. | $81.05 | 2024 | Ycanth |
| Regeneron Healthcare Solutions, INC. | $64.27 | 2024-2025 | Dupixent |
| Mayne Pharma Commercial LLC | $60.25 | 2023 | |
| Organon LLC | $23.28 | 2025 | Vtama |
| Botanix Sb INC | $21.90 | 2025 | Sofdra |
| Ucb, INC. | $21.79 | 2024 | Bimzelx |
| Leo Pharma INC. | $21.51 | 2023 | Adbry |
| Sebela Pharmaceuticals INC. | $21.41 | 2022 | |
| Biofrontera INC. | $19.85 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexa Toohey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.